SRF231 is a fully human monoclonal antibody that targets and inhibits the activity of the CD47 protein that is highly expressed in cancer cells. CD47 works as a signal that prevents cancer cells from being recognized by the immune system and macrophages. By blocking CD47 signaling, SRF231 may allow macrophages to recognize and destroy cancer cells.
SparkCures ID | 315 |
---|---|
Developed By | Surface Oncology |
Generic Name | SRF231 |
Treatment Classifications | |
Treatment Targets |
There are no resources, links or videos to display for this treatment.